ScreenPoint Medical’s Transpara breast imaging AI has been selected for a major randomized controlled trial aimed at evaluating AI in breast cancer screening.

The $16 million study, known as the PRISM Trial (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography), is funded by the Patient-Centered Outcomes Research Institute and will be led by researchers from UCLA and UC Davis.

This is the first large-scale trial of its kind in the United States to systematically assess whether AI can improve the accuracy of mammography, facilitate earlier cancer detection, and reduce unnecessary callbacks. The study will also measure patient and clinician attitudes toward AI through surveys and focus groups.
The trial will involve interpretation of hundreds of thousands of mammograms from participating academic medical centers, including UC San Diego, Boston Medical Center, University of Miami, University of Washington/Fred Hutchinson Cancer Center, and University of Wisconsin–Madison. Transpara will be integrated into clinical workflows using Aidoc’s aiOS platform.

“This landmark trial attests to three pillars: the pioneering vision of the researchers involved, PCORI's forward-thinking perspective on technology, and the potential of AI to help radiologists shape a healthier future,” said Pieter Kroese, chief executive officer of ScreenPoint Medical.

Transpara has been used to analyze more than 10 million mammograms globally and is currently deployed in screening programs and imaging departments in academic and clinical settings. The company, based in Nijmegen, Netherlands, positions the AI tool as a decision-support system designed to assist radiologists while keeping final diagnostic decisions in their hands.

The PRISM Trial is expected to produce prospective data that could inform broader adoption of AI tools in mammography, depending on outcomes related to diagnostic performance, workflow integration, and patient-centered care.

Artificial Intelligence Homepage